Compositions and methods for oral and/or mucosal administration of a biologically active agent are provided according to aspects of the present disclosure which include: a plurality of particles, wherein each particle has an exterior surface, the exterior surface defining a particle interior, the exterior surface having at least one type of zwitterionic polymer and/or zwitterionic copolymer disposed thereon and/or extending therefrom; and a biologically active agent disposed on the exterior surface and/or in the particle interior, wherein the biologically active agent is or includes a protein, peptide, or dietary supplement. According to particular aspects, compositions and methods for oral and/or mucosal administration of an anti diabetes biological agent, such as insulin and/or an insulin analog.

The invention provides compositions, formulations, and methods for treatment of malignancies via activation of an inflammatory response in the subject. Such compositions, formulations, and methods for are preferably used in conjunction with other therapies for the treatment and/or management of malignancies, e.g., chemotherapy and/or radiation. The invention also provides methods of monitoring immune activation in subjects with malignancies.

The invention provides compositions, formulations, and methods for treatment of malignancies via activation of an inflammatory response in the subject. Such compositions, formulations, and methods for are preferably used in conjunction with other therapies for the treatment and/or management of malignancies, e.g., chemotherapy and/or radiation. The invention also provides methods of monitoring immune activation in subjects with malignancies.

The invention provides compositions, formulations, and methods for treatment of malignancies via activation of an inflammatory response in the subject. Such compositions, formulations, and methods for are preferably used in conjunction with other therapies for the treatment and/or management of malignancies, e.g., chemotherapy and/or radiation. The invention also provides methods of monitoring immune activation in subjects with malignancies.

A solid form formulation comprising chromium (sucrosomial chromium®) or copper (sucrosomial copper®) or a vitamin (sucrosomial vitamin®) and related composition, process for the preparation and method for treatment of a chromium deficiency and/or a change in the carbohydrate metabolism and/or a change in the muscle energy metabolism are described.

A solid form formulation comprising chromium (sucrosomial chromium®) or copper (sucrosomial copper®) or a vitamin (sucrosomial vitamin®) and related composition, process for the preparation and method for treatment of a chromium deficiency and/or a change in the carbohydrate metabolism and/or a change in the muscle energy metabolism are described.

A solid form formulation based on a nutrient comprising: (a) a mineral or a vitamin, (b) a phospholipid, (c) a first agent selected from (c-i) carrageenan and (c-ii) acacia gum, and, optionally, (d) a sucrester and/or (e) a starch of plant origin and related composition, process of preparation and method of treatment of a deficiency of said mineral and/or vitamin are disclosed.

A solid form formulation based on a nutrient comprising: (a) a mineral or a vitamin, (b) a phospholipid, (c) a first agent selected from (c-i) carrageenan and (c-ii) acacia gum, and, optionally, (d) a sucrester and/or (e) a starch of plant origin and related composition, process of preparation and method of treatment of a deficiency of said mineral and/or vitamin are disclosed.

A solid form formulation based on a nutrient comprising: (a) a mineral or a vitamin, (b) a phospholipid, (c) a first agent selected from (c-i) carrageenan and (c-ii) acacia gum, and, optionally, (d) a sucrester and/or (e) a starch of plant origin and related composition, process of preparation and method of treatment of a deficiency of said mineral and/or vitamin are disclosed.

The present invention relates to topical pharmaceutical compositions for treatment or prophylaxis of onychomycosis, and other fungal conditions caused by Trichophyton rubrum and/or Trichophyton mentagrophytes, comprising an effective amount of an amine-based anti-fungal compound, such as terbinafine or a pharmaceutically acceptable salt thereof, and monocaprin, in certain proportions.